Cassie Jung, Chief Operating Officer of Aquestive Therapeutics, Inc. (NASDAQ:AQST), filed a Form 4 on September 8, 2026, disclosing the exercise of a Common Stock Purchase Warrant on September 3, 2026.

Key Highlights

  • Warrant exercised: Cassie Jung acquired 4,587 shares of Common Stock on September 3, 2026.
  • Exercise price: The warrant was exercised at $0.96 per share.
  • Post-transaction ownership: Jung directly holds 206,833 shares of Common Stock following the transaction.
  • Indirect ownership: An additional 2,000 shares are held indirectly by spouse.
  • Warrant origin: The warrant was issued on June 8, 2022, pursuant to a Securities Purchase Agreement dated June 6, 2022, and became exercisable on December 8, 2022.
  • Derivative position reduced to zero: Following the exercise, the number of warrants beneficially owned is reported as 0.

Details of the Warrant Exercise by Aquestive Therapeutics COO

According to the filing, Cassie Jung, who serves as Chief Operating Officer of Aquestive Therapeutics, Inc., exercised a Common Stock Purchase Warrant on September 3, 2026. The filing describes the transaction as "the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022." The warrant carried an exercise price of $0.96 per share and covered 4,587 shares of Common Stock.

The filing reports that the warrant became exercisable on December 8, 2022, and was set to expire on June 8, 2027. Following the exercise, the derivative security position is listed as 0, reflecting that the full warrant was used. The transaction code recorded is "X," and the price of the derivative security upon exercise is listed as $0.

After the reported transaction, Jung directly holds 206,833 shares of Aquestive Therapeutics Common Stock. An additional 2,000 shares are reported as held indirectly by spouse, with no transaction date listed for that position. The Form 4 was signed by Thomas Zalewski as Attorney-In-Fact and filed on September 8, 2026.

What Was Disclosed

The filing discloses a warrant exercise by Aquestive Therapeutics COO Cassie Jung, covering 4,587 shares of Common Stock at $0.96 per share on September 3, 2026, resulting in direct beneficial ownership of 206,833 shares and eliminating the derivative position.